

Preferred Choices Asthma Devices

Short Acting Beta 2 Agonist (SABA)

MDI

Salbutamol MDI + Spacer (Volumatic[®], Aerochamber Plus[®])

Alternative Device

Easyhaler[®] Salbutamol

Inhaled Corticosteroid (ICS)

MDI

Clenil Modulite[®] MDI + Spacer (Volumatic[®], Able Spacer[®], Optichamber[®])
Qvar[®] MDI + Spacer (Aerochamber plus[®], Able Spacer[®], Optichamber[®])

Alternative Device

Easyhaler[®] Beclometasone (not licensed in under 18 years)
Qvar Easi-Breathe[®]

Patients Aged 12-17

Easyhaler[®] Budesonide may be considered as an additional alternative in patients aged 12-17 if other licensed preferred choice ICS devices are not suitable.

Inhaled Corticosteroid/Long Acting Beta 2 agonist (ICS/LABA)

MDI

Fostair[®] MDI +Spacer (Aerochamber plus[®], Able Spacer[®], Optichamber[®]) (not licensed in under 18 years)

Flutiform[®] MDI +Spacer (Aerochamber plus[®], Able Spacer[®], Optichamber[®])
(250 strength not licensed in under 18 years)

Alternative Device

Fostair Nexthaler[®] (not licensed in under 18 years)

Patients Aged 12-17

Symbicort Turbohaler[®] and Seretide Accuhaler[®] should remain as alternative devices if MDI+spacer is not suitable for patients aged 12-17.

(Seretide Evohaler[®] may be used only if desirable to use Volumatic[®]) or if ICS/LABA with dose of fluticasone 250 indicated in patients aged 12-17)

Prescribing Clinical Network: Asthma Devices for Adults over 18 years February 2017

Inhaled Corticosteroid (ICS) / Long Acting Beta 2 agonist (LABA) combination choices and dosing.

Preferred choices are shown in bold. The remaining devices have been designated green by the Prescribing Clinical Network (PCN) however they should only be prescribed if the preferred choices have been tried and found not to be suitable for the patient.

The purpose of these tables is to clarify dosing regimen for LABA /ICS combinations following regular preventer therapy with low dose ICS (400mcg BDP per day) For management of asthma and detailed information on the place of other therapies: <https://www.britthoracic.org.uk/documentlibrary/clinicalinformation/asthma/btssign-asthma-guideline-2016>

Initial add-on therapy: Add inhaled LABA to low dose ICS (normally in a combination inhaler)

MDI + spacer (Starting Dose):

Fostair[®] 100/6 1 puff bd

(£14.66) or

Flutiform[®] 50/5 2 puffs bd

(£14.40) or

Seretide Evohaler[®] 50/25 2 puffs bd

£18.00)

Dry Powder Inhaler (DPI):

Fostair Nexthaler[®] 100/6 1 puff bd

(£14.66) or

Duoresp Spiromax[®] 160/4.5 1 puff bd

(£14.98) or

Seretide Accuhaler[®] 100/50 1 puff bd

(£18.00) or

Symbicort Turbohaler[®] 200/6 1 puff bd

(19.00)

Additional add-on therapies: Benefit from LABA but control still inadequate increase ICS dose to medium dose

MDI + spacer:

Fostair[®] 100/6 2 puffs bd

(£29.32) or

Flutiform[®] 125/5 MDI 2 puffs bd

(£28.00) or

Sirdupla[®] 125/25 2 puffs bd

(£26.25) or

Seretide Evohaler[®] 125/25 2 puffs bd

(£35.00)

Dry Powder Inhaler (DPI):

Fostair Nexthaler[®] 100/6 2 puffs bd

(£29.32) or

Duoresp Spiromax[®] 160/4.5 2 puffs bd

(£29.97) or

Seretide Accuhaler[®] 250/50 1 puff bd

(£35.00) or

Symbicort Turbohaler[®] 200/6 2 puffs bd

(£38.00)

High dose therapies: Consider trials of increasing ICS up to high dose
High Dose ICS Safety Card required for doses >1000mcg BDP equivalent/day

MDI + spacer:

Fostair[®] 200/6 2 puffs bd

(£29.32) or

Flutiform[®] 250/10 MDI 2 puffs bd

(£45.56) or

Sirdupla[®] 250 2 puffs bd

(£44.61) or

Seretide Evohaler[®] 250 2 puffs bd

(£59.48)

Dry Powder Inhaler (DPI):

Fostair Nexthaler[®] 200/6 2 puffs bd

(£29.32)

Duoresp Spiromax[®] 320 /9 2 puffs bd

(£59.94) or

Seretide Accuhaler[®] 500/50 1 puff bd

(£40.92) or

Symbicort Turbohaler[®] 400/12 2 puffs

bd (£76.00)

Costing for 30 days treatment from MIMS February 2017. SPCs <https://www.medicines.org.uk/emc/>

Spacer compatibility: <http://www.mims.co.uk/asthma-copd-preparations-compatible-devices/respiratory-system/article/882435>